company background image
CGS

CogstateASX:CGS Stock Report

Market Cap

AU$400.4m

7D

4.5%

1Y

136.7%

Updated

01 Dec, 2021

Data

Company Financials +
CGS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance3/6
Financial Health6/6
Dividends0/6

CGS Stock Overview

Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Cogstate
Historical stock prices
Current Share PriceAU$2.32
52 Week HighAU$2.49
52 Week LowAU$0.80
Beta-0.25
1 Month Change0%
3 Month Change43.21%
1 Year Change136.74%
3 Year Change268.25%
5 Year Change110.91%
Change since IPO364.00%

Recent News & Updates

Oct 20
We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

Performance at Cogstate Limited ( ASX:CGS ) has been reasonably good and CEO Brad O'Connor has done a decent job of...

Shareholder Returns

CGSAU Healthcare ServicesAU Market
7D4.5%3.0%-1.9%
1Y136.7%59.5%11.7%

Return vs Industry: CGS exceeded the Australian Healthcare Services industry which returned 59.5% over the past year.

Return vs Market: CGS exceeded the Australian Market which returned 11.7% over the past year.

Price Volatility

Is CGS's price volatile compared to industry and market?
CGS volatility
CGS Average Weekly Movement8.1%
Healthcare Services Industry Average Movement8.2%
Market Average Movement8.3%
10% most volatile stocks in AU Market15.9%
10% least volatile stocks in AU Market3.6%

Stable Share Price: CGS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CGS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999164Brad O'Connorhttps://www.cogstate.com

Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company’s services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments.

Cogstate Fundamentals Summary

How do Cogstate's earnings and revenue compare to its market cap?
CGS fundamental statistics
Market CapUS$284.12m
Earnings (TTM)US$5.23m
Revenue (TTM)US$32.69m

54.3x

P/E Ratio

8.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CGS income statement (TTM)
RevenueUS$32.69m
Cost of RevenueUS$15.21m
Gross ProfitUS$17.48m
ExpensesUS$12.25m
EarningsUS$5.23m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.03
Gross Margin53.48%
Net Profit Margin16.01%
Debt/Equity Ratio0%

How did CGS perform over the long term?

See historical performance and comparison

Valuation

Is Cogstate undervalued compared to its fair value and its price relative to the market?

54.29x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CGS (A$2.32) is trading above our estimate of fair value (A$1.72)

Significantly Below Fair Value: CGS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CGS is good value based on its PE Ratio (54.3x) compared to the Global Healthcare Services industry average (64.5x).

PE vs Market: CGS is poor value based on its PE Ratio (54.3x) compared to the Australian market (12.6x).


Price to Earnings Growth Ratio

PEG Ratio: CGS is poor value based on its PEG Ratio (1.6x)


Price to Book Ratio

PB vs Industry: CGS is overvalued based on its PB Ratio (13x) compared to the XX Healthcare Services industry average (4.1x).


Future Growth

How is Cogstate forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

33.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CGS's forecast earnings growth (33.8% per year) is above the savings rate (1.9%).

Earnings vs Market: CGS's earnings (33.8% per year) are forecast to grow faster than the Australian market (11.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CGS's revenue (22.2% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: CGS's revenue (22.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CGS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Cogstate performed over the past 5 years?

6.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CGS has a large one-off gain of $2.4M impacting its June 30 2021 financial results.

Growing Profit Margin: CGS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CGS has become profitable over the past 5 years, growing earnings by 6.2% per year.

Accelerating Growth: CGS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CGS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare Services industry (33.1%).


Return on Equity

High ROE: CGS's Return on Equity (24%) is considered high.


Financial Health

How is Cogstate's financial position?


Financial Position Analysis

Short Term Liabilities: CGS's short term assets ($34.1M) exceed its short term liabilities ($18.9M).

Long Term Liabilities: CGS's short term assets ($34.1M) exceed its long term liabilities ($10.7M).


Debt to Equity History and Analysis

Debt Level: CGS is debt free.

Reducing Debt: CGS had no debt 5 years ago.

Debt Coverage: CGS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CGS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Cogstate current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CGS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CGS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Brad O'Connor

16yrs

Tenure

US$1,076,087

Compensation

Mr. Bradley O'Connor, also known as Brad, B.Bus, CA, has been the Chief Executive Officer and Managing Director of Cogstate Limited since December 1, 2005 and served as its Chief Financial Officer since Ma...


CEO Compensation Analysis

Compensation vs Market: Brad's total compensation ($USD1.08M) is above average for companies of similar size in the Australian market ($USD544.14K).

Compensation vs Earnings: Brad's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CGS's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: CGS's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CGS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cogstate Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Cogstate Limited
  • Ticker: CGS
  • Exchange: ASX
  • Founded: 1999
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$400.436m
  • Shares outstanding: 172.60m
  • Website: https://www.cogstate.com

Number of Employees


Location

  • Cogstate Limited
  • 425 Smith Street
  • Suite 117
  • Fitzroy
  • Victoria
  • 3065
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/01 15:37
End of Day Share Price2021/12/01 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.